Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 22, 2021

BeiGene commences Phase I trial of TYK2 inhibitor BGB-23339

The trial will analyse the safety, tolerability, pharmacokinetics and initial activity of BGB-23339 in healthy people. 

BeiGene has dosed the first subject in a Phase I clinical trial of its experimental tyrosine kinase 2 (TYK2) inhibitor, BGB-23339, being developed to potentially treat multiple immune-mediated disorders.

A potent, greatly-selective, allosteric inhibitor of TYK2, BGB-23339 acts on TYK2’s regulatory pseudokinase (JH2) domain.

TYK2 is a key mediator in cytokine signalling pathways that have been linked to various multiple immune-mediated diseases, including psoriasis and inflammatory bowel disease.

The randomised, first-in-human trial will assess the safety, tolerability, pharmacokinetics, as well as initial activity of BGB-23339.

BeiGene expects to enrol a total of up to 115 healthy subjects in Australia and/or China.

The number of subjects experiencing adverse events (AEs), clinically substantial differences from baseline in vital signs will be the primary outcomes of the trial.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

BeiGene R&D global head Lai Wang said: “Discovered and developed by BeiGene, BGB-23339 is a highly selective, potent, allosteric TYK2 inhibitor that has shown promising activity in preclinical evaluation.

“Building on our proven track record in oncology, BeiGene is expanding its clinical focus to discover new modalities and platforms in areas of high unmet need, including inflammation and immunology, to bring innovative, impactful medicines to patients.”

In preclinical trials, BGB-23339 showed robust selectivity to hinder interleukin (IL)-12, IL-23, and Type 1 interferons (IFNs). These pro-inflammatory cytokines play a pivotal role in triggering inflammation, BeiGene noted.

Another internally developed asset of the company, Brukinsa (zanubrutinib) is presently being analysed in a Phase II trial in individuals with active proliferative lupus nephritis.

Brukinsa is a highly selective BTK inhibitor.

Last month, BeiGene obtained regulatory approval in Australia for Brukinsa for the treatment of subjects with Waldenström’s macroglobulinemia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU